Ultragenyx Pharmaceutical (RARE) Change in Acquisitions & Divestments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Change in Acquisitions & Divestments for 14 consecutive years, with $88.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 35.77% year-over-year to $88.0 million; the TTM figure through Mar 2026 stood at $395.0 million (up 3424.9% YoY), while the FY2025 annual figure was $444.0 million, up 14700.0% from the prior year.
• Change in Acquisitions & Divestments climbed to $88.0 million in Q1 2026 per RARE's latest filing, from $82.1 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $257.9 million in Q2 2022 and bottomed at -$287.7 million in Q4 2024.
• Historically, Change in Acquisitions & Divestments has averaged $39.4 million across 5 years, with a median of $82.1 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments soared 386.02% — and 2024, when it slumped 8366.52%.
• Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments stood at $1.3 million in 2022, then soared by 165.85% to $3.5 million in 2023, then plunged by 8366.52% to -$287.7 million in 2024, then soared by 128.54% to $82.1 million in 2025, then grew by 7.17% to $88.0 million in 2026.
• Business Quant data shows RARE's Change in Acquisitions & Divestments at $88.0 million in Q1 2026, $82.1 million in Q4 2025, and $135.6 million in Q3 2025.